Immune checkpoint blockade for Merkel cell carcinoma: actual findings and unanswered questions

Valentina Guarnotta; Manuela Albertelli; Annamaria Colao; Lena Bottiglieri; Erika Maria Grossrubatscher; Giovanni Vitale; Giovanna Muscogiuri; Pasqualino Malandrino; Genoveffa Pizza; Manila Rubino; Andrea Isidori; Federica Grillo; Carla Di Dato; Roberta Modica; Federica De Cicco; Fabio Lo Calzo; Elia Guadagno; Barbara Altieri; Laura Rizza; Sergio Di Molfetta; Concetta Sciammarella; Francesco Ferraù; Annamaria Colao; Erika Messina; Chiara Martini; Elisa Giannetta; Elena Ambrosetti; Marco Gallo; Antonio Bianchi; Giovanni Vitale; Silvia Carra; Lena Bottiglieri; Giovanni Vitale; Sergio Di Molfetta; Lena Bottiglieri; Paola Razzore; Maria Chiara Zatelli; Giuseppe Fanciulli; Antonella Di Sarno; Antongiulio Faggiano; Rosaria Maddalena Ruggeri; Diego Ferone; Severo Campione; Elisa Giannetta; Marco Gallo

Immune checkpoint blockade for Merkel cell carcinoma: actual findings and unanswered questions

Valentina Guarnotta, Manuela Albertelli, Annamaria Colao, Lena Bottiglieri, Erika Maria Grossrubatscher, Giovanni Vitale, Giovanna Muscogiuri, Pasqualino Malandrino, Genoveffa Pizza, Manila Rubino, Andrea Isidori, Federica Grillo, Carla Di Dato, Roberta Modica, Federica De Cicco, Fabio Lo Calzo, Elia Guadagno, Barbara Altieri, Laura Rizza, Sergio Di MolfettaConcetta Sciammarella, Francesco Ferraù, Annamaria Colao, Erika Messina, Chiara Martini, Elisa Giannetta, Elena Ambrosetti, Marco Gallo, Antonio Bianchi, Giovanni Vitale, Silvia Carra, Lena Bottiglieri, Giovanni Vitale, Sergio Di Molfetta, Lena Bottiglieri, Paola Razzore, Maria Chiara Zatelli, Giuseppe Fanciulli, Antonella Di Sarno, Antongiulio Faggiano, Rosaria Maddalena Ruggeri, Diego Ferone, Severo Campione, Elisa Giannetta, Marco Gallo

Promozione della Salute, Materno-Infantile, di Medicina Interna e Specialistica di Eccellenza “G. D’Alessandro”

Risultato della ricerca: Article › peer review

10 Citazioni (Scopus)

Abstract

PURPOSE:Merkel cell carcinoma (MCC) is a rare, aggressive neuroendocrine carcinoma arising from the skin. We aimed to review and deal with some of the most relevant controversial topics on the correct use of immunotherapy for the treatment of MCC.METHODS:The primary search was carried out via PubMed, EMBASE, and the Cochrane Library (until 31st May, 2018), while other articles and guidelines were retrieved from related papers or those referenced in these papers. Additionally, we performed an extensive search on ClinicalTrials.gov to gather information on the ongoing clinical trials related to this specific topic.RESULTS:We performed an up-to-date critical review taking into account the results of both retrospective and prospective published studies evaluating these issues: Are there any predictive criteria of response to immunotherapy? What is the correct place of immunotherapy in the treatment algorithm of MCC? What is the best choice after immunotherapy failure? What to do with patients for whom immunotherapy is not been feasible or contraindicated? How long should immunotherapy be prolonged, and what follow-up should be offered after complete response?CONCLUSION:The therapeutic landscape of MCC is rapidly evolving: many open issues will probably be resolved, and many other questions are likely to arise in the next few years. The results of ongoing prospective clinical trials and of several other studies on these issues are eagerly awaited

Lingua originale	English
pagine (da-a)	429-443
Numero di pagine	15
Rivista	Journal of Cancer Research and Clinical Oncology
Volume	145
Stato di pubblicazione	Published - 2019

All Science Journal Classification (ASJC) codes

???subjectarea.asjc.2700.2730???
???subjectarea.asjc.1300.1306???

Altri file e collegamenti

Cita questo

Guarnotta, V., Albertelli, M., Colao, A., Bottiglieri, L., Grossrubatscher, E. M., Vitale, G., Muscogiuri, G., Malandrino, P., Pizza, G., Rubino, M., Isidori, A., Grillo, F., Di Dato, C., Modica, R., De Cicco, F., Lo Calzo, F., Guadagno, E., Altieri, B., Rizza, L., ... Gallo, M. (2019). Immune checkpoint blockade for Merkel cell carcinoma: actual findings and unanswered questions. Journal of Cancer Research and Clinical Oncology, 145, 429-443.

Guarnotta, V, Albertelli, M, Colao, A, Bottiglieri, L, Grossrubatscher, EM, Vitale, G, Muscogiuri, G, Malandrino, P, Pizza, G, Rubino, M, Isidori, A, Grillo, F, Di Dato, C, Modica, R, De Cicco, F, Lo Calzo, F, Guadagno, E, Altieri, B, Rizza, L, Di Molfetta, S, Sciammarella, C, Ferraù, F, Colao, A, Messina, E, Martini, C, Giannetta, E, Ambrosetti, E, Gallo, M, Bianchi, A, Vitale, G, Carra, S, Bottiglieri, L, Vitale, G, Di Molfetta, S, Bottiglieri, L, Razzore, P, Zatelli, MC, Fanciulli, G, Di Sarno, A, Faggiano, A, Ruggeri, RM, Ferone, D, Campione, S, Giannetta, E & Gallo, M 2019, 'Immune checkpoint blockade for Merkel cell carcinoma: actual findings and unanswered questions', Journal of Cancer Research and Clinical Oncology, vol. 145, pagg. 429-443.

@article{3a44bbb747b04f8793549594ddac8fb4,

title = "Immune checkpoint blockade for Merkel cell carcinoma: actual findings and unanswered questions",

abstract = "PURPOSE:Merkel cell carcinoma (MCC) is a rare, aggressive neuroendocrine carcinoma arising from the skin. We aimed to review and deal with some of the most relevant controversial topics on the correct use of immunotherapy for the treatment of MCC.METHODS:The primary search was carried out via PubMed, EMBASE, and the Cochrane Library (until 31st May, 2018), while other articles and guidelines were retrieved from related papers or those referenced in these papers. Additionally, we performed an extensive search on ClinicalTrials.gov to gather information on the ongoing clinical trials related to this specific topic.RESULTS:We performed an up-to-date critical review taking into account the results of both retrospective and prospective published studies evaluating these issues: Are there any predictive criteria of response to immunotherapy? What is the correct place of immunotherapy in the treatment algorithm of MCC? What is the best choice after immunotherapy failure? What to do with patients for whom immunotherapy is not been feasible or contraindicated? How long should immunotherapy be prolonged, and what follow-up should be offered after complete response?CONCLUSION:The therapeutic landscape of MCC is rapidly evolving: many open issues will probably be resolved, and many other questions are likely to arise in the next few years. The results of ongoing prospective clinical trials and of several other studies on these issues are eagerly awaited",

author = "Valentina Guarnotta and Manuela Albertelli and Annamaria Colao and Lena Bottiglieri and Grossrubatscher, {Erika Maria} and Giovanni Vitale and Giovanna Muscogiuri and Pasqualino Malandrino and Genoveffa Pizza and Manila Rubino and Andrea Isidori and Federica Grillo and {Di Dato}, Carla and Roberta Modica and {De Cicco}, Federica and {Lo Calzo}, Fabio and Elia Guadagno and Barbara Altieri and Laura Rizza and Sergio Di Molfetta and Concetta Sciammarella and Francesco Ferra{\`u} and Annamaria Colao and Erika Messina and Chiara Martini and Elisa Giannetta and Elena Ambrosetti and Marco Gallo and Antonio Bianchi and Giovanni Vitale and Silvia Carra and Lena Bottiglieri and Giovanni Vitale and Sergio Di Molfetta and Lena Bottiglieri and Paola Razzore and Zatelli, {Maria Chiara} and Giuseppe Fanciulli and {Di Sarno}, Antonella and Antongiulio Faggiano and Ruggeri, {Rosaria Maddalena} and Diego Ferone and Severo Campione and Elisa Giannetta and Marco Gallo",

year = "2019",

language = "English",

volume = "145",

pages = "429--443",

journal = "Journal of Cancer Research and Clinical Oncology",

issn = "0171-5216",

publisher = "Springer Verlag",

}

TY - JOUR

T1 - Immune checkpoint blockade for Merkel cell carcinoma: actual findings and unanswered questions

AU - Guarnotta, Valentina

AU - Albertelli, Manuela

AU - Colao, Annamaria

AU - Bottiglieri, Lena

AU - Grossrubatscher, Erika Maria

AU - Vitale, Giovanni

AU - Muscogiuri, Giovanna

AU - Malandrino, Pasqualino

AU - Pizza, Genoveffa

AU - Rubino, Manila

AU - Isidori, Andrea

AU - Grillo, Federica

AU - Di Dato, Carla

AU - Modica, Roberta

AU - De Cicco, Federica

AU - Lo Calzo, Fabio

AU - Guadagno, Elia

AU - Altieri, Barbara

AU - Rizza, Laura

AU - Di Molfetta, Sergio

AU - Sciammarella, Concetta

AU - Ferraù, Francesco

AU - Colao, Annamaria

AU - Messina, Erika

AU - Martini, Chiara

AU - Giannetta, Elisa

AU - Ambrosetti, Elena

AU - Gallo, Marco

AU - Bianchi, Antonio

AU - Vitale, Giovanni

AU - Carra, Silvia

AU - Bottiglieri, Lena

AU - Vitale, Giovanni

AU - Di Molfetta, Sergio

AU - Bottiglieri, Lena

AU - Razzore, Paola

AU - Zatelli, Maria Chiara

AU - Fanciulli, Giuseppe

AU - Di Sarno, Antonella

AU - Faggiano, Antongiulio

AU - Ruggeri, Rosaria Maddalena

AU - Ferone, Diego

AU - Campione, Severo

AU - Giannetta, Elisa

AU - Gallo, Marco

PY - 2019

Y1 - 2019

N2 - PURPOSE:Merkel cell carcinoma (MCC) is a rare, aggressive neuroendocrine carcinoma arising from the skin. We aimed to review and deal with some of the most relevant controversial topics on the correct use of immunotherapy for the treatment of MCC.METHODS:The primary search was carried out via PubMed, EMBASE, and the Cochrane Library (until 31st May, 2018), while other articles and guidelines were retrieved from related papers or those referenced in these papers. Additionally, we performed an extensive search on ClinicalTrials.gov to gather information on the ongoing clinical trials related to this specific topic.RESULTS:We performed an up-to-date critical review taking into account the results of both retrospective and prospective published studies evaluating these issues: Are there any predictive criteria of response to immunotherapy? What is the correct place of immunotherapy in the treatment algorithm of MCC? What is the best choice after immunotherapy failure? What to do with patients for whom immunotherapy is not been feasible or contraindicated? How long should immunotherapy be prolonged, and what follow-up should be offered after complete response?CONCLUSION:The therapeutic landscape of MCC is rapidly evolving: many open issues will probably be resolved, and many other questions are likely to arise in the next few years. The results of ongoing prospective clinical trials and of several other studies on these issues are eagerly awaited

AB - PURPOSE:Merkel cell carcinoma (MCC) is a rare, aggressive neuroendocrine carcinoma arising from the skin. We aimed to review and deal with some of the most relevant controversial topics on the correct use of immunotherapy for the treatment of MCC.METHODS:The primary search was carried out via PubMed, EMBASE, and the Cochrane Library (until 31st May, 2018), while other articles and guidelines were retrieved from related papers or those referenced in these papers. Additionally, we performed an extensive search on ClinicalTrials.gov to gather information on the ongoing clinical trials related to this specific topic.RESULTS:We performed an up-to-date critical review taking into account the results of both retrospective and prospective published studies evaluating these issues: Are there any predictive criteria of response to immunotherapy? What is the correct place of immunotherapy in the treatment algorithm of MCC? What is the best choice after immunotherapy failure? What to do with patients for whom immunotherapy is not been feasible or contraindicated? How long should immunotherapy be prolonged, and what follow-up should be offered after complete response?CONCLUSION:The therapeutic landscape of MCC is rapidly evolving: many open issues will probably be resolved, and many other questions are likely to arise in the next few years. The results of ongoing prospective clinical trials and of several other studies on these issues are eagerly awaited

UR - http://hdl.handle.net/10447/367320

UR - https://www.ncbi.nlm.nih.gov/pubmed/30617553

M3 - Article

VL - 145

SP - 429

EP - 443

JO - Journal of Cancer Research and Clinical Oncology

JF - Journal of Cancer Research and Clinical Oncology

SN - 0171-5216

ER -

Immune checkpoint blockade for Merkel cell carcinoma: actual findings and unanswered questions

Abstract

All Science Journal Classification (ASJC) codes

Altri file e collegamenti

Fingerprint

Cita questo